-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LCqX7qUSV7yzqE6Ifmof7vootxMGtEFqLueA0KkgJTjEYFUf1TdHgBsRSS5DI4Ob IfDo4OK9ChDljpwBOKE1YA== 0001108017-06-000387.txt : 20060515 0001108017-06-000387.hdr.sgml : 20060515 20060515172625 ACCESSION NUMBER: 0001108017-06-000387 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060331 FILED AS OF DATE: 20060515 DATE AS OF CHANGE: 20060515 EFFECTIVENESS DATE: 20060515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Worldwide Biotech & Pharmaceutical CO CENTRAL INDEX KEY: 0000095302 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-GROCERIES & RELATED PRODUCTS [5140] IRS NUMBER: 590950777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06914 FILM NUMBER: 06843020 BUSINESS ADDRESS: STREET 1: 110 SARASOTA QUAY CITY: SARASOTA STATE: FL ZIP: 34236 BUSINESS PHONE: 941-365-2521 MAIL ADDRESS: STREET 1: 110 SARASOTA QUAY CITY: SARASOTA STATE: FL ZIP: 34236 FORMER COMPANY: FORMER CONFORMED NAME: SUN CITY INDUSTRIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SUN CITY DAIRY PRODUCTS INC DATE OF NAME CHANGE: 19690727 NT 10-Q 1 wwbio12b25.htm NT-10Q NT-10Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25
NOTIFICATION OF LATE FILING

Commission File Number: 000-28173
CUSIP Number: 83082V 207
 
(Check one)[  ] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [ X ] Form 10-Q and Form 10-QSB [ ] Form N-SAR

For Period Ended: March 31, 2006

[ ] Transition Report on Form 10-K and Form 10-KSB
 
[ ] Transition Report on Form 20-F
 
[ ] Transition Report on Form 11-K
 
[ ] Transition Report on Form 10-Q and Form 10-QSB
 
[ ] Transition Report on Form N-SAR
 
For Transition Period Ended:

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission hasverified any information contained herein.
If the notification relates to a portion of the filing checked above, identifythe item(s) to which the notification relates:

-1-
PART I - REGISTRANT INFORMATION
Full Name of Registrant:
Worldwide Biotech and Pharmaceutical Company
Former Name if Applicable:
Address of Principal Executive Office:
4 Fenghui South Road, Jie Zuo Mansion, 15th Floor, A10-11501, Xi’an, Shaanxi, P.R. China, 710075
 
PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, 10-QSB, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
 
[   ] (c) The accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

-2-
PART III - NARRATIVE

  State below in reasonable detail the reasons why Form 10-K, 10-KSB, 11-K, 20-F, 10-Q, 10-QSB, N-SAR, or the transition report or portion thereof could not be filed within the prescribed period. (Attach extra sheets if needed.)
 
The Registrant's quarterly report on Form 10-QSB could not be filed within the prescribed time period due to the Registrant and its accountants requiring additional time to prepare and review the financial statements of the Registrant for the quarter ended March 31, 2006.  Such delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company will file its Form 10-QSB no later than the fifth calendar day following the prescribed due date.
 
PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification
Wenxia Guo         86-29-88193339
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

[X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof:

[ ] Yes [X ] No

If so attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Worldwide Biotech and Pharmaceutical Company
(Name of Registrant as Specified in Charter)
 
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
 
Worldwide Biotech and Pharmaceutical Company
 
 		  
 		  
 
Date: May 11, 2006 By:   /s/ Wenxia Guo
 
Wenxia Guo
 
Chief Executive Officer

 
-3-
 -----END PRIVACY-ENHANCED MESSAGE-----